Clindamycin Gel (clindamycin ) — Competitive Intelligence Brief

Clindamycin Gel (clindamycin ) (Clindamycin Gel (clindamycin )) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Lincosamide antibiotic. Area: Dermatology.

marketed Lincosamide antibiotic Bacterial 50S ribosomal subunit Dermatology Small molecule

Target snapshot

Clindamycin Gel (clindamycin ) (Clindamycin Gel (clindamycin )) — Stiefel, a GSK Company. Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Clindamycin Gel (clindamycin ) TARGET	Clindamycin Gel (clindamycin )	Stiefel, a GSK Company	marketed	Lincosamide antibiotic	Bacterial 50S ribosomal subunit
Linezolid antimicrobial-lock solution	Linezolid antimicrobial-lock solution	Clinica Universidad de Navarra, Universidad de Navarra	marketed	Oxazolidinone antibiotic	Bacterial 50S ribosomal subunit
Clarithromycin (ST14)	Clarithromycin (ST14)	National Taiwan University Hospital	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit
Azithromycin 1gm	Azithromycin 1gm	Ain Shams Maternity Hospital	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit
clarithromycin, rifabutin	clarithromycin, rifabutin	The University of Texas Health Science Center at Tyler	marketed	Macrolide antibiotic and rifamycin antibiotic combination	Bacterial 50S ribosomal subunit (clarithromycin); bacterial RNA polymerase (rifabutin)
Oral Suspension Tedizolid Phosphate	Oral Suspension Tedizolid Phosphate	Merck Sharp & Dohme LLC	marketed	Oxazolidinone antibiotic	Bacterial 50S ribosomal subunit
CLDM 1% gel	CLDM 1% gel	GlaxoSmithKline	marketed	Lincosamide antibiotic	Bacterial 50S ribosomal subunit

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Lincosamide antibiotic class)

1. GlaxoSmithKline · 2 drugs in this class
2. Balmoral Medical company · 1 drug in this class
3. Generic (originally Upjohn/Pfizer) · 1 drug in this class
4. Hospital General Universitario Elche · 1 drug in this class
5. Janssen-Cilag, S.A. · 1 drug in this class
6. Jinnah Postgraduate Medical Centre · 1 drug in this class
7. Oral and Maxillofacial Surgery Clinic, Poland · 1 drug in this class
8. Stiefel, a GSK Company · 1 drug in this class
9. Actavis Inc. · 1 drug in this class
10. University of Toronto · 1 drug in this class